Felipe Eduardo Soto

Mr. Felipe Eduardo Soto

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
ABAlvaro Becerra
Alvaro Becerra
FSFelipe Eduardo Soto
Felipe Eduardo Soto
DMDaniela Millán
Daniela Millán
JVJuan Jose Valenzuela
Juan Jose Valenzuela
MDMaria Paz Moya Daza
Maria Paz Moya Daza
MCManuel E Cortés
Manuel E Cortés
Background: Buddleja globosa Hope (matico) is a Chilean medicinal plant traditionally used in Mapuche and Aymara ethnomedicine. However, no systematic synthesis of its phytochemical composition and pharmacological evidence has been previously reported. Methods: A PRISMA 2020-compliant systematic review was conducted using Google Scholar, PubMed, EBSCOhost, and Springer Nature databases from inception to March 2026. Studies reporting phytochemical characterization and/or biological activities of B. globosa were included. Methodological quality was assessed using an adapted five-criterion tool for non-clinical studies. The protocol was registered in OSF. Results: Fourteen studies (1989–2026), mainly from Chilean research groups, identified 27 bioactive compounds across leaves, roots, and flowers. These included phenylethanoid glycosides (e.g., verbascoside/acteoside, echinacoside, forsitoside B, and linarin), flavonoids (luteolin 7-O-glucoside, apigenin 7-O-glucoside, myricetin, catechin, and epicatechin), pentacyclic triterpenes (α/β-amyrins and β-sitosterol), iridoid glycosides, and clerodane diterpenoids (buddledines A–C), as well as four newly reported phenylethanoids. Antioxidant activity was the most frequently evaluated endpoint (11/14 studies), mainly mediated through hydrogen atom transfer and single-electron transfer mechanisms linked to caffeoyl and flavonoid structures. Anti-inflammatory effects (five studies) involved COX and 5-LOX inhibition and reduced PGE2 production in LPS-stimulated macrophages. Additional reported activities included antihepatotoxic, antiplatelet, wound-healing, antibacterial, and antifungal effects. Conclusions:B. globosa exhibits a coherent phytochemical profile supporting strong preclinical antioxidant and anti-inflammatory activities. The main limitation for clinical translation is the low oral bioavailability of phenylethanoid glycosides. Nanoformulation strategies, investigation of colonic metabolites, and topical delivery systems represent promising approaches to bridge the preclinical-to-clinical gap.

27 January 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
ABAlvaro Becerra
Alvaro Becerra
FSFelipe Eduardo Soto
Felipe Eduardo Soto
AOAlejandro Gabriel Vallejos Olivos
Alejandro Gabriel Vallejos Olivos
DMDaniela Millán
Daniela Millán
JVJuan Jose Valenzuela
Juan Jose Valenzuela
MCManuel E Cortés
Manuel E Cortés
Background: Parthenocissus quinquefolia (Virginia creeper), widely distributed and used in Chile, lacks a systematic characterization of its bioactive components. This study synthesizes the evidence on the phytochemical composition and biological activities of P. quinquefolia, with emphasis on metabolites involved in redox regulation and inflammation. Methods: A systematic review was conducted following PRISMA 2020 guidelines. Searches were performed across four electronic databases, including original studies reporting antioxidant and anti-inflammatory effects. Results: Of 665 records identified, 14 studies met the inclusion criteria. Phytochemical analyses revealed phenolic compounds, particularly flavonoids (e.g., catechin, epicatechin, gallocatechin, epigallocatechin, quercetin, rutin, isoquercitrin, myricetin, luteolin, naringin) and stilbenes (e.g., ε-viniferin, miyabenol C). These metabolites exhibit antioxidant activity through ROS scavenging, metal chelation, and Nrf2/ARE activation. Anti-inflammatory effects were attributed to the downregulation of NF-κB, AP-1, and MAPK signaling, inhibition of NLRP3 inflammasome activation, and suppression of COX-2/iNOS expression. Conclusions: P. quinquefolia is a rich source of phenolic metabolites with robust antioxidant and anti-inflammatory mechanisms. The consistency of molecular responses across studies highlights its potential as a promising candidate for phytotherapeutic development targeting oxidative stress and inflammatory pathways.

16 May 2026 in Revista de la Facultad de Medicina
Verified
Journal Article
Open access
PDF file
FSFelipe Eduardo Soto
Felipe Eduardo Soto
JVJuan Jose Valenzuela
Juan Jose Valenzuela
ÁGÁlvaro González
Álvaro González
ABAlvaro Becerra
Alvaro Becerra
Introduction: Long COVID is an emerging global health issue characterized by multiple adverse outcomes, frequently resulting in the onset of several conditions, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Objective: To analyze the prevalence of ME/CFS symptoms (duration >6 months) among patients with long COVID. Materials and methods: This systematic review adhered to the PRISMA 2020 guidelines (PROSPERO registration: CDR42024557707). In May 2024, a systematic search was conducted in Medline, EBSCOhost, Scopus, and Web of Science to identify studies reporting data on the presence of ME/CFS symptoms in long COVID patients (>6 months post-infection). Manual searches were also performed in Google Scholar. Study quality was assessed using the Newcastle-Ottawa scale. ME/CFS symptoms were classified according to the Institute of Medicine (IOM) 2015 diagnostic criteria. Results: Eleven studies were included in the review: 10 cohorts (7 prospective, 3 retrospective) and 1 cross-sectional study. The aggregate sample size was 453 586 persons with long COVID. The most frequent ME/CFS symptoms in these patients were fatigue (56.99%), cognitive impairment (44.54%), post-exertional malaise (41.55%), unrefreshing sleep (41.08%), new-onset severe headaches following SARS-CoV-2 infection (31.21%), and myalgia (20.59%). Conversely, the least prevalent symptoms were lymph node tenderness or swelling (5.38%), sensitivity to light and sound (4.75%), and nausea (0.17%). No studies reported patients with chills, night sweats, or food allergies or sensitivities. Conclusion: A considerable proportion of patients with long COVID met the IOM 2015 criteria for ME/CFS. Fatigue, cognitive impairment, post-exertional malaise, unrefreshing sleep, and new-onset severe headaches following SARS-CoV-2 infection were the most frequent symptoms, with prevalences >41% in individual studies. The observed methodological heterogeneity highlights the need for multicenter longitudinal studies to determine the prevalence of ME/CFS and its symptoms in this population and, thus, to guide therapeutic interventions.

15 June 2026 in Journal of Infection and Public Health
Verified
Journal Article
Open access
ABAlvaro Becerra
Alvaro Becerra
NRNicolás Rebolledo
Nicolás Rebolledo
FSFelipe Eduardo Soto
Felipe Eduardo Soto
JVJuan José Valenzuela-Fuenzalida
Juan José Valenzuela-Fuenzalida
JLJessica Paola Loaiza-Giraldo
Jessica Paola Loaiza-Giraldo
Jose Leon-RojasJose Leon-Rojas
Jose Leon-Rojas
Sepsis-induced neuromuscular dysfunction (SIND) is a common but underrecognized complication in critically ill patients, contributing to prolonged intensive care unit (ICU) stays, increased morbidity, and long-term functional impairment. Its pathophysiology is multifactorial, involving interactions among host factors, disease severity, and therapeutic interventions. To systematically identify and classify risk factors associated with SIND in septic patients and to estimate its pooled prevalence across clinical studies. A systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD42024577234). Databases; Medline, BMC, Cochrane Library, and Google Scholar, were searched for relevant studies. Fourteen studies including 596 adult patients with sepsis were eligible. Risk factors were categorized into seven clinical domains and further stratified as modifiable or non-modifiable. Pooled prevalence estimates were calculated using a random-effects model (DerSimonian-Laird method). A total of 40 clinical parameters were identified and grouped into seven categories: baseline characteristics, organ failure, disease severity indices, medical procedures, plasma biomarkers, pharmacological therapy, and length of stay. The pooled prevalence of SIND was 60% (95% CI: 50-70%), with substantial heterogeneity. ICU-acquired neuromuscular dysfunction showed a prevalence of 70% (95% CI: 60-80%), whereas direct neuromuscular damage attributable to sepsis was lower (9%, 95% CI: 4-19%). Critical illness polyneuropathy was the most frequently reported entity and demonstrated strong associations with both modifiable and non-modifiable risk factors. SIND is a highly prevalent and multifactorial complication of sepsis. Early recognition of risk factors-particularly modifiable ones-may support targeted preventive strategies and improve clinical outcomes in critically ill patients.